This is a multicenter, double-blind, randomized, placebo-controlled, dose-response study to evaluate the safety and efficacy of emricasan in improving portal hypertension in subjects with NASH cirrhosis and severe portal hypertension (defined as hepatic venous pressure gradient (HVPG) ?12 mmHg). Subjects can have compensated (at least 60% of subjects but no more than 75%) or decompensated cirrhosis with no more than 1 prior significant decompensating event and must be currently clinically stable on stable standard therapy [2] (see Inclusion/Exclusion criteria).

This is a long-term extension study to evaluate the safety of filgotinib administered to subjects with Crohns Disease (CD).

This is a Phase 2 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of filgotinib in treating subjects with SBCD. Approximately 100 subjects aged 18 to 75 years with SBCD will be randomized to 1 of 3 treatment groups in a 2:2:1 ratio to receive filgotinib 200 mg, filgotinib 100 mg or matching placebo.

This is an open-label, multicenter, extension trial to evaluate the long term safety and efficacy of RPC1063 in patients with moderately to severely active ulcerative colitis (UC). Patients who have previously participated in a trial of RPC1063 for UC will be eligible for entry in this trial if they meet the eligibility criterion for participation as outlined in the prior trial.

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, and efficacy of SER-109 versus placebo in adult subjects 18 years of age or older with recurrent CDI, defined as: a history of 3 CDI episodes within 9 months, inclusive of the current episode designed to demonstrate the superiority of SER-109 versus placebo to reduce recurrence of Clostridium difficile infection (CDI) in adults who have received antibacterial drug treatment for recurrent CDI (RCDI), based on the proportion of subjects experiencing a CDI recurrence

ECOSPOR IV is an open-label extension of Study SERES-012. This study is designed to evaluate the safety, tolerability, and efficacy of a treatment regimen SER-109 in adult subjects 18 years of age or older with recurrent Clostridium difficile infection (RCDI), who received a treatment regimen of SER-109 or placebo in Study SERES012 and had adequate clinical response following the standard of care antibiotic therapy. For this study, CDI recurrence during the study is defined by the following criteria: Positive CDI test on a stool sample determined by a toxin assay, ?

The major goal of this project is the development of qualified animal models for Marburg Disease. Txbiomed Project: 4700

The major goal of this project is the development of qualified animal models for Marburg Disease.

This is a phase 2, double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of filgotinib in the treatment of perianal fistulizing Crohn’s Disease (CD). Approximately 75 subjects aged 18 to 75 years with perianal fistulizing CD will be randomized to 1 of 3 treatment groups in a 2:2:1 ratio

This is a long-term extension study to evaluate the safety of filgotinib administered to subjects with Ulcerative Colitis (UC).